J Korean Diabetes.  2014 Sep;15(3):178-184. 10.4093/jkd.2014.15.3.178.

Two Cases of Diabetic Ketoacidosis Associated with Paliperidone Treatment in Schizophrenia

• Kim HH
• Yang HK
• Ham H
• Jeon HW
• Lee JY
• Hwang SW
• Jang BH
• Min GJ
• Lee JM
• Lee SH

• KMID: 2173893
• DOI: http://doi.org/10.4093/jkd.2014.15.3.178

Abstract

Atypical antipsychotics, which have better efficacy and fewer side effects compared to first-generation antipsychotics, are being used increasingly for the treatment of schizophrenia. However, adverse events such as weight gain, diabetes mellitus and abnormal lipid profile have been reported in patients treated with these agents. Diabetic ketoacidosis (DKA) is a rare side effect of atypical antipsychotics, but deserves attention due to its severity. Although various atypical antipsychotics have been reported as causing DKA, there have been no reports showing an association with DKA and paliperidone, which is a recently developed antipsychotic agent. Here, we report two cases of DKA in patients with paliperidone therapy. Both cases had no history of diabetes before use of paliperidone, and DKA was manifested within 2 years of starting paliperidone therapy. Like other atypical antipsychotics, use of paliperidone warrants monitoring for metabolic derangements including DKA.

Keyword

Diabetic ketoacidosis; Paliperidone; Schizophrenia

MeSH Terms

Antipsychotic Agents
Diabetes Mellitus
Diabetic Ketoacidosis*
Humans
Schizophrenia*
Weight Gain
Antipsychotic Agents

Reference

1. Freedman R. Schizophrenia. N Engl J Med. 2003; 349:1738–49.

2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19(Suppl 1):1–93.

3. Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl). 2013; 226:1–12.

4. Two cases of diabetic ketoacidosis associated with atypical antipsychotics. J Korean Diabetes Assoc. 2005; 29:566–70.

5. Lee IJ, Kim HS, Kang JG, Kim CS, Ihm SH, Yoo HJ, Lee SJ. A case of diabetic ketoacidosis associated with longterm risperidone use. Korean J Med. 2009; 77:S1212–6.

6. Kim SH, Woo J. A case of diabetic ketoacidosis by olanzapine. J Korean Neuropsychiatr Assoc. 2007; 46:262–6.

7. Jeon YJ, Lee SH, Jang SN, Kim JH, Hong SH, Cho JH, Kwon HS, Yoon KH, Cha BY, Son HY. Diebetic ketoacidosis in a patient with longterm clozapine therapy. J Korean Endocr Soc. 2007; 22:376–80.

8. Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW. Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investig. 2012; 32:497–512.

9. Rodríguez-Martínez A, Quilo CG. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective. Clin Drug Investig. 2013; 33:867–76.

10. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005; 66:504–14.

11. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008; 13:27–35.

12. Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, Fletcher P, Guenette M, Cohn T, Wolever T, Arenovich T, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 2011; 131:90–5.

13. Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013; 12:22.

14. Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol. 2008; 23:343–56.

15. Sliwa JK, Fu DJ, Bossie CA, Turkoz I, Alphs L. Body mass index and metabolic parameters in patients with schizophrenia during longterm treatment with paliperidone palmitate. BMC Psychiatry. 2014; 14:52.

16. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008; 29:292–302.

17. Liu B, Yu C, Li Q, Li L. Ketosis-onset diabetes and ketosis-prone diabetes: same or not? Int J Endocrinol. 2013; 2013:821403.

18. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004; 65:267–72.

19. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010; 10:209–16.

20. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes. 2009; 3:5–15.